Plus   Neg

Kiniksa Pharma: KPL-716 Phase 1a/1b Achieves Its Study Goals

Kiniksa Pharmaceuticals, Ltd. (KNSA) presented Phase 1a/1b clinical data for KPL-716, an investigational fully-human monoclonal antibody that targets oncostatin M receptor beta. In the First-in-Human clinical trial, single intravenous and subcutaneous doses of KPL-716 were well-tolerated in both adult healthy volunteers and adult subjects with moderate-to-severe atopic dermatitis experiencing moderate-to-severe pruritus. KPL-716 also demonstrated a reduction in pruritus. The company said the results support its plans for expanding clinical development into multiple chronic pruritic diseases, including prurigo nodularis.

"Data from the single-dose cohorts of the placebo-controlled Phase 1a/1b of KPL-716 achieved the goals established for the study. The results provided us with data on the safety and tolerability of KPL-716 as well as the anti-pruritic effect of the drug," said Sanj Patel, CEO and Chairman of the Board of Kiniksa.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walmart Inc. launched its first-ever car seat recycling event at nearly 4,000 stores across the country in partnership with waste management company TerraCycle. Customers who trade in used car seats at participating Walmart stores will receive a $30 Walmart gift card that can be used in store or online to buy items for their baby. Any brand of car seat is accepted through the program. Amazon Music launched a premium quality music service, Amazon Music HD, with more than 50 million songs in High Definition. The service also has millions of songs in Ultra High Definition. It is available for streaming in the U.S., U.K., Germany and Japan. Apple, Inc. is set to launch the much awaited Apple Arcade for mobile, desktop and the living room on September 19, 2019 in more than 150 countries. The world's first game subscription service can be accessed from an all-new tab on the App Store across iOS, macOS and tvOS. Apple Arcade will be available on the App Store on iOS 13. It will be available on iPadOS and tvOS 13 on September 30.
Follow RTT